| Authors: |
Izutsu K; Department of Hematology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp., Akahane D; Department of Hematology, Tokyo Medical University, Tokyo, Japan., Toubai T; Department of Internal Medicine III, Division of Hematology and Cell Therapy, Faculty of Medicine, Yamagata University, Yamagata, Japan., Saito T; Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan., Mishima Y; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Fujisaki T; Department of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan., Nishikori M; Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kumode T; Department of Hematology and Rheumatology, Kindai University, Osaka, Japan., Suehiro Y; Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Ishitsuka K; Department of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan., Patah P; AbbVie, North Chicago, IL, USA., Takahashi A; Genmab, Tokyo, Japan., Månsson BD; Genmab, Copenhagen, Denmark., Favaro E; Genmab, Copenhagen, Denmark., Fukuhara N; Department of Hematology, Tohoku University, Sendai, Japan. |
